News | October 16, 2024
Akums Drugs enters into license and distribution agreement with Triple Hair, Canada
Akums Drugs will undertake this development and commercialization in India
Akums Drugs will undertake this development and commercialization in India
he company will focus on production of any pharmaceutical and biotechnological products
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
PEKK is a high-performance polymer family used in aerospace and other demanding markets
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Subscribe To Our Newsletter & Stay Updated
